ORI Capital
ORI Capital is a venture capital firm founded in 2015, focusing on investing in innovative early-stage biotech companies globally. The firm targets areas such as diagnostics, drug delivery, and therapeutics, particularly in disease areas with high mortality rates like cancer, cardiovascular, and neurodegenerative diseases. ORI Capital aims to be financially successful for its investors while being socially impactful to patients worldwide.
ORI Capital
4727-34, Sun Hung Kai Centre, 30 Harbour Road, Wanchai, Hong Kong
Portfolio
Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections. The company aims to utilize Induced Pluripotent Stem Cell (iPS) derived pancreatic islets to cure insulin dependent diabetes.
#Biotechnology
World’s first fully humanized antibodies selection platform generating disease-modifying drugs.
#Biotechnology
World’s leading gene therapy company targeting multiple diseases with limited or no existing treatment.
#Gene Therapy
It is the only company to date that can deliver drugs to pancreatic tumors using its innovative delivery device.
#Biotechnology
Key People
Founder & Senior Partner
Partner
Operating Partner
Director
Investment Associate
Approach-specific Scientist